Ana I. Gil
Research Subjects
Ana I. Gil has a total of 198 co-authors. Here are the top co-authors by number of shared publications:
- Bia Peña
Instituto de Investigación Nutricional, Lima, Peru
3 shared publications - Claudio F. Lanata
Instituto de Investigación Nutricional, Lima, Peru
3 shared publications - Mayra Ochoa
Instituto de Investigación Nutricional, Lima, Peru
3 shared publications - Carlos R. Celis
Instituto de Investigación Nutricional, Lima, Peru
2 shared publications - Lucie Ecker
Instituto de Investigación Nutricional, Lima, Peru
2 shared publications - Omar Flores
Instituto de Investigación Nutricional Lima Peru
2 shared publications
Latest Publications
- Open Access
- 20 March 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (4) , ofaf157
Pandemic Social Distancing and Declines in Nasopharyngeal Carriage of Pneumococcus and Related Antimicrobial-Resistant Genes: Evidence From Household-Based Cohort Studies in Lima, Peru
Background: Peru implemented restrictive social distancing policies during the COVID-19 pandemic. Few studies have examined patterns of nasopharyngeal pneumococcal carriage and related antimicrobial-resistant genes (ARGs), particularly in community-based settings with intense social distancing policies. Methods: Nasopharyngeal swabs were systematically obtained weekly from children and adults enrolled in 2 household-based prospective cohorts in Lima, Peru: prepandemic (2019–2020) and pandemic (2020–2021). Selected samples underwent sequencing-based detection of Streptococcus pneumoniae and related ARGs. We compared detections of pneumococcus and erm genes between cohorts during the same 7 epidemiologic weeks in 2020 and 2021 while accounting for relevant covariates and household clustering by mixed effects logistic regression models. Results: An overall 663 specimens from 114 individuals were included: 407 and 256 samples from the prepandemic and pandemic cohorts, respectively. Carriage of pneumococcus was lower in the pandemic cohort (3.5%) as compared with the prepandemic cohort (23.6%; adjusted odds ratio, 0.09; 95% CI, .02–.32). Similarly, erm gene carriage was lower in the pandemic cohort (28.1%) as compared with the prepandemic cohort (58.7%; adjusted odds ratio, 0.21; 95% CI, .10–.46). Conclusions: We observed a substantial reduction in the carriage of S pneumoniae and related ARGs in community-dwelling individuals during a pandemic period with intense social distancing in Lima, Peru.
- 20 March 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (4) , ofaf157
Open AccessPandemic Social Distancing and Declines in Nasopharyngeal Carriage of Pneumococcus and Related Antimicrobial-Resistant Genes: Evidence From Household-Based Cohort Studies in Lima, Peru
Background: Peru implemented restrictive social distancing policies during the COVID-19 pandemic. Few studies have examined patterns of nasopharyngeal pneumococcal carriage and related antimicrobial-resistant genes (ARGs), particularly in community-based settings with intense social distancing policies. Methods: Nasopharyngeal swabs were systematically obtained weekly from children and adults enrolled in 2 household-based prospective cohorts in Lima, Peru: prepandemic (2019–2020) and pandemic (2020–2021). Selected samples underwent sequencing-based detection of Streptococcus pneumoniae and related ARGs. We compared detections of pneumococcus and erm genes between cohorts during the same 7 epidemiologic weeks in 2020 and 2021 while accounting for relevant covariates and household clustering by mixed effects logistic regression models. Results: An overall 663 specimens from 114 individuals were included: 407 and 256 samples from the prepandemic and pandemic cohorts, respectively. Carriage of pneumococcus was lower in the pandemic cohort (3.5%) as compared with the prepandemic cohort (23.6%; adjusted odds ratio, 0.09; 95% CI, .02–.32). Similarly, erm gene carriage was lower in the pandemic cohort (28.1%) as compared with the prepandemic cohort (58.7%; adjusted odds ratio, 0.21; 95% CI, .10–.46). Conclusions: We observed a substantial reduction in the carriage of S pneumoniae and related ARGs in community-dwelling individuals during a pandemic period with intense social distancing in Lima, Peru.
- Open Access
Proteomics as a complementary approach to measure norovirus infection in clinical samples
- Top Cited Papers
- 23 November 2021
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 22 (3) , 329-340
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial
- 23 November 2021
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 22 (3) , 329-340
Top Cited PapersEfficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial
- Open Access
- 2 October 2021
- Published by Fundacion Instituto Hipolito Unanue in Diagnóstico
- Vol. 60 (3) , 156-165
Desarrollo de las Vacunas contra el SARS-CoV-2 y las implicancias relacionadas a la aparición de las variantes del virus
La aparición de la pandemia causada por el virus SARS-CoV-2 tomó desprevenido al mundo entero. Sin embargo, la reacción ha sido asombrosa. En poco más de un año de la aparición del virus, se cuenta con cientos de vacunas en desarrollo y varias de ellas vienen siendo aplicadas en casi todo el mundo. En este manuscrito revisamos el estado actual del desarrollo de las vacunas, resaltando aquéllas que cuentan con estudios de Fase III (eficacia) o IV (efectividad). Además, revisamos las variantes de interés y de preocupación del virus SARS-CoV-2 detectadas hasta el momento y qué se sabe sobre de la eficacia de las vacunas contra ellas.
- 2 October 2021
- Published by Fundacion Instituto Hipolito Unanue in Diagnóstico
- Vol. 60 (3) , 156-165
Open AccessDesarrollo de las Vacunas contra el SARS-CoV-2 y las implicancias relacionadas a la aparición de las variantes del virus
La aparición de la pandemia causada por el virus SARS-CoV-2 tomó desprevenido al mundo entero. Sin embargo, la reacción ha sido asombrosa. En poco más de un año de la aparición del virus, se cuenta con cientos de vacunas en desarrollo y varias de ellas vienen siendo aplicadas en casi todo el mundo. En este manuscrito revisamos el estado actual del desarrollo de las vacunas, resaltando aquéllas que cuentan con estudios de Fase III (eficacia) o IV (efectividad). Además, revisamos las variantes de interés y de preocupación del virus SARS-CoV-2 detectadas hasta el momento y qué se sabe sobre de la eficacia de las vacunas contra ellas.